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Abstract: A detailed understanding of the stability of an active pharmaceutical ingredient and a
pharmaceutical dosage form is essential for the drug-development process and for safe and effective
use of medicines. Photostability testing as an inherent part of stability studies provides valuable
knowledge on degradation pathways and structures of products generated under UV irradiation.
Photostability is particularly important for topically administered drugs, as they are more exposed
to UV radiation. Bexarotene is a more recent third-generation retinoid approved by the U.S. Food
and Drug Administration and the European Medicines Agency as a topically applied anticancer
agent. The present study aimed to assess bexarotene photostability, including the presence of UV
filters, which have been permitted to be used in cosmetic products in Europe and the USA. The
bexarotene photostability testing was performed in ethanol solutions and in formulations applied
on PMMA plates. The UPLC-MS/MS technique was used to determine the tested substance. The
presence of photocatalysts such as TiO2 or ZnO, as well as the organic UV filters avobenzone,
benzophenone-3, meradimate, and homosalate, could contribute to degradation of bexarotene under
UV irradiation. Four photocatalytic degradation products of bexarotene were identified for the
first time. The antiproliferative properties of the degradation products of bexarotene were assessed
by MTT assay on a panel of human adherent cancer cells, and concentration-dependent growth
inhibition was evidenced on all tested cell lines. The cytotoxicity of the formed products after 4 h of
UV irradiation was significantly higher than that of the parent compound (p < 0.05). Furthermore non-
cancerous murine fibroblasts exhibited marked concentration-dependent inhibition by bexarotene,
while the degradation products elicited more pronounced antiproliferative action only at the highest
applied concentration.
Keywords: bexarotene; photostability; UV absorbers; third-generation retinoids
1. Introduction
The development of pharmaceuticals aims to introduce new drug products in the
market. This process has general requirements established by The International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH
provides guidelines on quality, safety, efficacy, and multidisciplinary topics. The quality
guidelines are divided into 14 categories (ICH Q1–Q14), and provide comprehensive
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recommendations and methodologies based on good manufacturing practices. The Q1A–
Q1F stability documents address the stability testing of both new drug substances and
products, and are related to the influence of humidity, temperature, pH, the presence of
oxidizing agents, and light on their chemical and physical state. The annex to the main
stability guideline is the Photostability Testing of New Drug Substances and Products (Q1B)
implemented in Europe on 1 December 1996 and in the USA on 1 May 1997. This document
states that light testing should constitute an integral part of stress testing of new drug
substances and products [1]. The degradation products are potential impurities of drugs in
addition to other organic (e.g., substrates from synthesis process, reagents, catalysts) and
inorganic impurities (e.g., reagents, catalysts, heavy metals) [2,3].
Retinoids have become increasingly popular in recent years as an active ingredient of
drugs and cosmetics. These drugs are intended for topical and systemic treatment of skin
disorders including acne, psoriasis, and cancer, as well as an option to prevent and mini-
mize signs of aging [4–6]. Three generations of retinoids are distinguished, with substantial
differences in their structures. Recently, trifarotene, the first fourth-generation retinoid, has
been reported for the treatment of acne vulgaris [7,8]. Because retinoids are commonly
applied directly to the skin, their photostability should be thoroughly investigated [9].
Retinoids are a heterogeneous group of compounds in terms of photostability [10]. Most
photostability studies have been conducted for first-generation retinoids, e.g., retinol,
tretinoin, and isotretinoin. The results of these studies indicated that these compounds
could undergo degradation under UV irradiation, which leads to the loss of activity, or can
even cause photoreaction, phototoxicity, and photocarcinogenicity [11,12]. They have been
found to undergo photoisomerization, photooxidation, and photodegradation [12]. This is
due to the presence of conjugated double bonds in their molecules. Because the physico-
chemical properties of the first-generation retinoids are known, attempts have been made
to improve their photostability while retaining their original activity. Further searches for
the derivatives of known retinoids revealed that synthetic polyaromatic retinoids showed
promising photostability. Third-generation retinoids include adapalene, tazarotene, and
bexarotene. They were designed by cyclization of the polyene side chain, and thus gained
a more rigid structure [13]. It is widely known that third-generation retinoids are more
photostable than the first-generation ones. Nonetheless, because little is known about their
potential photodegradation pathways and the structure of their degradation products,
it would be useful to elucidate these phenomena. Degradation of active pharmaceutical
ingredients is a highly complex process that is affected by different factors.
The stability of micronised bexarotene has been determined according to ICH storage
conditions. Furthermore, photostability investigations confirmed the stability of bexarotene,
but it should be protected from extreme heat and from excessive light exposure [14]. Be-
cause of the lack of detailed information on the photostability of a more recent third-
generation retinoid—bexarotene—the present study aimed to assess the effect of UV
irradiation on its stability. Bexarotene (Targretin) gel and Targretin capsules have been
approved by the U.S. Food and Drug Administration and the European Medicines Agency
as an anticancer agent for the treatment of cutaneous T-cell lymphoma [15]. Retinoids
are a powerful class of compounds that are currently being tested for anticancer activ-
ity [16]. Recently, bexarotene has also been extensively studied for its application in the
treatment of non-small-cell lung cancer—oral bexarotene in combination with cisplatin
and vinorelbine [17]; advanced or metastatic non-small-cell lung cancer—comparison of
carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel [18]; metastatic
breast cancer [19]; aerodigestive tract cancer—first clinical trial of combination of erlotinib
with bexarotene [20]; and acute myeloid leukemia [21]. Bexarotene, as a selective agonist
of retinoid X receptors (RXRs), plays a significant role in cell proliferation, differentiation,
and apoptosis. Bexarotene has been proven to have neuroprotective potential in ischemic
stroke [22] and traumatic brain injury [23], and in models of Parkinson’s disease [24] and
Alzheimer’s disease [25]. Moreover, retinoid receptors are expressed in epithelial ovarian
cancer and may indicate an poor prognosis, and for these reasons, retinoids may be used in
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the treatment of ovarian and breast cancers. Bexarotene has also been used experimentally
to prevent breast cancer in women with genetic risk [26].
A significant and often neglected issue is the comprehensive study of the photostability
of pharmaceuticals [27]. Although the photostability testing of pharmaceuticals covers
their manufacturing process and storage, it is also necessary to test photostability to enable
the effective administration of drugs [9]. An extremely valuable research subject for topical
agents applied to the skin is to assess the influence of UV absorbers on their photostability
in different UVA and UVB irradiation ranges. Chemical and physical UV absorbers act by
blocking different wavelengths to protect the skin from harmful effects of sunlight. The
U.S. Food and Drug Administration regulates sun-protection products as over-the-counter
drugs. However, in Europe, they are considered to be cosmetics. The toxicological activity
of the degradation products can be observed in many pharmaceutically active substances
and medicinal products, which in some cases may influence the therapeutic effect [28].
Photodegradation products are impurities that can affect drug safety and quality [29].
Therefore, it is necessary to define their structures and amounts to assess the toxicity and
risk related to their presence in pharmaceutical products. In recent years, the application
of in vitro models in evaluating the toxicity is increasing [30]. Numerous toxicity tests,
including toxic/genotoxic risks and phototoxicity, should be carried out to investigate the
potential hazardous effects caused by the presence of degradation products.
Therefore, we performed a detailed investigation on the photostability of bexarotene
in ethanol solutions and in prepared formulations applied on poly(methyl methacrylate)
(PMMA) plates. Selected UV absorbers, which have been permitted to be used in cosmetic
products in Europe and the USA, were used in the study to assess their impact on the
stability of bexarotene under UV irradiation. The UPLC-MS/MS experiments were carried
out for quantitative determinations of the investigated compound and identification of
its photodegradation products. The in vitro assessment of the antiproliferative potential
of the degradation products of bexarotene was performed using non-cancerous murine
fibroblasts and human cancer cell lines isolated from breast (MDA-MB-231), cervix (HeLa),
and ovarian (A2780) cancers.
2. Experimental
2.1. Materials and Methods
2.1.1. Reagents
Bexarotene (4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic
acid) was purchased from Sigma-Aldrich (St. Louis, MO, USA). HPLC-grade methanol,
acetonitrile, and formic acid (98%) were purchased from J.T. Baker. Ethanol (99.8%) was
obtained from POCH (Gliwice, Poland). Water (quadruple-distilled) with a conductivity of
less than 1 µS cm−1 was prepared using an S2-97A2 distillation apparatus (ChemLand, Star-
gard Szczecin, Poland). Zinc oxide (nanopowder, < 100 nm particle size) and titanium(IV)
oxide (anatase, nanopowder, < 25 nm particle size, 99.7% (metal basis)) were purchased
from Sigma-Aldrich. UV absorbers, namely avobenzone (AVB), 3-(4-methylbenzylidene)
camphor (MBC), benzophenone-1 (BP-1), benzophenone-2 (BP-2), benzophenone-3 (BP-3),
benzophenone-4 (BP-4), octocrylene (OC), homosalate, and meradimate, were obtained
from Sigma-Aldrich. The formulation consisted of hydroxypropylcellulose (Klucel, Ger-
many) and propylene glycol (VWR BDH Chemicals, France).
2.1.2. Preparation of Reagent Solutions
A stock solution of bexarotene was prepared at a concentration of 0.2 mg mL−1 in
a 50 mL volumetric flask by dissolving a weighted portion of the standard substance in
ethanol, and the solution was then stored at 2–8 ◦C for no longer than 3 days. To validate
the method, seven solutions with bexarotene concentrations of 0.01, 0.025, 0.05, 0.075, 0.1,
0.15, and 0.2 mg mL−1 were prepared.
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2.1.3. Bexarotene Gel Preparation (1 mg g−1)
A total of 20.475 g of anhydrous alcohol was weighed in a beaker, and 0.025 g of
bexarotene was added. Subsequently, 3.75 g of propylene glycol and 0.75 g of hydrox-
ypropylcellulose were added. The entire mixture was mixed using the T10 basic ULTRA-
TURRAX® homogenizer (IKA, Königswinter, Germany) at the lowest rotational speed
(8000 rpm) for 40 min.
2.1.4. Photostability Tests of Bexarotene in Ethanolic Solution
The irradiation of the bexarotene was conducted in ethanolic solutions with a con-
centration of 0.1 mg mL−1. The photodegradation experiments were performed in quartz
Petri dishes with Ø of 50 mm (Hornik, Poland), covered with quartz covers to prevent
any evaporation of ethanol, and secured with a parafilm. Next, 2 mL of the solution was
placed on a quartz Petri dish and irradiated for 1 h at 500 W m−2 (cumulative dose of
ultraviolet radiation: 218 kJ m−2) with a solar light simulator (Suntest CPSþ, Atlas, Ger-
many) equipped with an optical filter for blocking wavelengths shorter than 290 nm and
an IR-block filter to neutralize thermal effects.
Photocatalytic degradation experiments of bexarotene in ethanolic solution were
performed with the addition of a TiO2/ZnO suspension in ethanol (50 mg TiO2/50 mg
ZnO in a 5 mL flask). Briefly, 2 mL of solution containing 1 mL of bexarotene stock solution,
0.5 mL of ethanol, and 0.5 mL of TiO2/ZnO suspension was added to quartz Petri dishes
and then exposed to irradiation. Analogously prepared samples covered with aluminum
foil were used as dark controls. Samples were filtered through a 0.45 µm pore-size filter
before the UPLC-MS/MS analysis. For chemical UV filters, 2 mL of solution containing
1 mL of stock solution of bexarotene, 0.2 mL of the investigated UV filter solution in ethanol,
and 0.8 mL of ethanol was irradiated, and the samples were then analyzed by UPLC-MS.
Three replicates of samples were prepared.
2.2. Photostability Tests of Bexarotene in Gel Formulation
2.2.1. Preparation of Chemical Filters
First, 10 mg of a chemical filter was weighed in Eppendorf vials, which were filled
with 1 g of propylene glycol. The entire mixture was mixed until complete dissolution
was obtained.
2.2.2. Preparation of Paste with Titanium(IV) Oxide and Zinc(II) Oxide at 5%
Concentration
First, 5 g of paste containing 5% TiO2/ZnO (1:1, w/w) was prepared. Next, 0.125 g of
each oxide was added to a mortar, followed by 4.75 g PEG 400. In addition, 5 g of paste
with titanium(IV) oxide at 5% concentration was prepared. Then, 0.250 g TiO2 was weighed
in a mortar, followed by the addition of 4.75 g of PEG 400.
2.2.3. Preparation of Gels Containing Bexarotene and UV Filters
One gram of gel containing bexarotene and a 100 mg solution containing a UV filter
were weighed. Both components were then mixed.
2.2.4. Photostability Tests of Bexarotene in Gel Preparation
First, 50 mg of gel containing bexarotene and a UV filter was weighed onto each
PMMA plate. The gel was evenly spread and left to dry for 10 min. The samples were
then irradiated for 2 h. In addition, PMMA plates with gel containing only the active
substance and with gel not containing the active substance and UV filter were prepared.
After irradiation, the PMMA plates were rinsed with 2.5 mL ethanol. The samples were
left alone for complete ethanol evaporation. The residues were dissolved in 0.5 mL ethanol,
and the samples were then filtered through a syringe filter (nylon, 0.45 µm) prior to the
UPLC-MS/MS analysis.
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3. UPLC-MS/MS Analysis
The UPLC-MS/MS system comprised a Waters ACQUITY UPLC (Waters Corporation,
Milford, MA, USA) coupled to a Waters TQD mass spectrometer (electrospray ionization
mode: ESI-tandem quadrupole). Chromatographic separations were performed using an
Acquity UPLC BEH (bridged ethyl hybrid) C18 column; 2.1 × 100 mm and 1.7 µm particle
size, equipped with an Acquity UPLC BEH C18 VanGuard Pre-column; 2.1 × 5 mm and
1.7 µm particle size. The column was maintained at 40 ◦C and eluted under gradient
conditions from 95% to 0% of eluent A over 10 min at a flow rate of 0.3 mL min−1 (eluent
A: water/formic acid (0.1%, v/v); eluent B: acetonitrile/formic acid (0.1%, v/v)). Chro-
matograms were acquired using a Waters eλ PDA detector. According to the formula
%i = (Ai/(∑A) × 100), compound concentration (%i) after degradation of bexarotene was
calculated as the quotient of the peak area (Ai) to the sum of all peak areas (∑A) on chro-
matograms. Spectra were analyzed in the 200–700 nm range with 1.2 nm resolution and a
sampling rate of 20 points s−1. MS detection settings for the Waters TQD mass spectrometer
were as follows: source temperature, 150 ◦C; desolvation temperature, 350 ◦C; desolvation
gas flow rate, 600 L h−1; cone gas flow, 100 L h−1; capillary potential, 3.00 kV; and cone
potential, 30 V. Nitrogen was used as both the nebulizing and drying gas. The data were
obtained in the scan mode ranging from 50 to 1000 m/z in time intervals of 0.5 s; eight scans
were summed up to obtain the final spectrum. Collision-activated dissociation analyses
were performed at an energy of 50 eV. Consequently, the ion spectra were obtained by
scanning in the m/z 50 to 350 range. MassLynx V 4.1 software (Waters) was used for
data acquisition.
4. Method Validation
The UPLC method was validated for the determination of bexarotene in the presence
of photodegradation products in accordance with International Conference on Harmonisa-
tion, 2005. Validation of the method included an evaluation of the following parameters:
specificity, linearity, limit of quantitation (LOQ), limit of detection (LOD), and precision.
5. In Vitro Cytotoxicity Assays
5.1. Investigated Solutions
The stock solution of bexarotene in ethanol was prepared in a 10 mL flask at a concen-
tration of 10 Mm. The prepared samples, containing 2 mL of the above solution with the
additional 10 mg of TiO2/ZnO (1;1, w/w), were placed into quartz dishes. The samples
were irradiated for 1, 2, and 4 h in a solar light simulator. Later, the samples were filtered
through a 0.45 µm filter before testing their antiproliferative properties.
5.2. Cell Lines and Cell Growth Inhibitory Assay
Human cancer cell lines isolated from breast (MDA-MB-231), cervix (HeLa), and ovar-
ian (A2780) cancers were purchased from the European Collection of Cell Cultures (ECCAC,
Salisbury, UK). Cells were cultivated in minimal essential medium supplemented with
10% fetal bovine serum, 1% antibiotic–antimycotic mixture, and non-essential amino acids
All media and supplements were obtained from Lonza Group Ltd. (Basel, Switzerland).
Near-confluent cells were seeded onto a 96-well microplate at a density of 5000 cells/well,
and after overnight standing, new medium containing the tested substance dissolved
in DMSO was added. After incubation for 72 h at 37 ◦C in humidified air containing
5% CO2, the viability of the cells was determined by the addition of 20 µL of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5 mg/mL) solution. After a 4 h
contact period, the medium was removed, and the precipitated formazan crystals were
dissolved in 100 µL of DMSO during a 60 min period of shaking. Finally, the produced
formazan was assayed at 545 nm, using a microplate reader utilizing wells with untreated
cells as control [25]. The highest concentration of DMSO (0.3%) exerted no substantial
action on the growth of the utilized cells. All in vitro experiments were carried out on two
microplates with at least five parallel wells.
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5.3. In Silico Toxicity Prediction
The OSIRIS Property Explorer was used to predict mutagenicity, tumorigenicity, irritation,
and reproductive effects of bexarotene and its photocatalytic degradation products [31].
6. Statistical Analysis
Statistical analyses were performed using Statistica v. 12 (StatSoft) and GraphPad
Prism (GraphPad Software, San Diego, CA, USA). For statistical analysis of cell death, a two-
way analysis of variance (ANOVA) with Tukey’s multiple-comparisons test was conducted.
Differences were considered statistically significant in comparison with untreated controls
when p ≤ 0.05.
7. Results and Discussion
Method Validation
The validation of the UPLC-MS/MS method confirmed its applicability for bexarotene
photostability assessment. The developed method was specific to bexarotene and coexisting
degradation products in the tested solutions, as well as in the prepared formulations.
The specificity of the method was evaluated by the assessment of blank chromatograms,
chromatograms of the pure standard substance, and chromatograms of bexarotene after
degradation. Furthermore, the resolution of the investigated chemical UV absorbers and
bexarotene was verified. Unfortunately, octocrylene and bexarotene were not well resolved;
thus, the former compound was excluded from the subsequent study. The chromatographic
separation of the other UV filters under study and bexarotene in ethanolic solutions was
satisfactory, both before and after UV irradiation (Figure 1). In the next step, the separation
of bexarotene and UV absorbers under study applied in the prepared formulations was
verified to assess the potential interference with ingredients. The chromatograms of the
samples of gel and gel with the addition of bexarotene and UV absorbers applied on PMMA
plates were analyzed before and after their UV irradiation. No additional peaks were
derived from gel ingredients. Least squares linear regression was applied to statistically
evaluate the peak areas vs concentration of bexarotene relationship. The method linearity
was determined for the concentration range of 0.01 mg/ mL−1 to 0.2 mg/ mL−1. The
linear regression equation was y = 14555.1 × −67351. The correlation coefficient and
determination coefficient (R2) obtained for the linear model were found to be 0.9987 and
0.9973, respectively. The y-intercept was statistically nonsignificant. The Shapiro–Wilk test
was used to confirm normality assumption; the significance value (p = 0.2526) was >0.05,
and hence, the residuals were considered to be normally distributed. On the basis of the
standard error of residuals and the slope of the calibration plot, the calculated LOQ and
LOD values were 0.01 and 0.04 mg mL−1, respectively. The precision was determined by the
analysis of six replicates of bexarotene solutions at a single concentration of 0.1 mg mL−1
(%RSD = 0.83%).
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Figure 1. UPLC-MS/MS analysis of photostability of bexarotene: (A) pure standard substance; (B) photocatalytic degra-
dation of bexarotene in ethanol solution after exposure to UV irradiation for 1 h in the presence of ZnO/TiO2; (C) bexar-
otene with BP-2 in ethanol solution after exposure to UV irradiation for 1 h; (D) bexarotene gel 1 mg g−1 with the addition 
of AVB after exposure to UV irradiation for 2 h. 
Figure 1. UPLC-MS/MS analysis of photostability of bexarotene: (A) pure standard substance; (B) photocatalytic degrada-
tion of bexarotene in ethanol solution after exposure to UV irradiation for 1 h in the presence of ZnO/TiO2; (C) bexarotene
with BP-2 in than l solution after exp sure to UV irradiation for 1 h; (D) bexarotene gel 1 mg g−1 with the addition of AVB
after exposure to UV irradiation for 2 h.
Pharmaceutics 2021, 13, 1220 8 of 18
8. Photostability Studies
Identification of Degradation Photoproducts
The metabolism of bexarotene in patients with advanced skin lesions of cutaneous
T-cell lymphoma was investigated following oral doses. Peak plasma concentrations were
observed at 2 h after administration. Plasma protein binding of bexarotene is almost
99%, which has a significant impact on its distribution, elimination, and pharmacolog-
ical effects [32,33]. After topical administration of bexarotene, a very low serum level
(< 5 ng mL−1) was observed [33]. Bexarotene is primarily metabolized in the liver. Both
6- and 7-hydroxy-bexarotene and 6- and 7-oxo-bexarotene are the major metabolites of
bexarotene that have been identified in plasma. The major cytochrome responsible for the
formation of the oxidative metabolites of bexarotene is cytochrome P450 3A4 [34]. The
oxidative metabolites are active in in vitro assays of retinoid receptor activation [35]. Pho-
tostability studies could provide valuable information about unwanted compounds that
can develop during manufacturing, storage, and therapeutic use of drugs. The degradation
products of bexarotene were identified by MS/MS analyses. The proposed structures of
the degradation products are shown in Table 1, and the proposed fragmentation patterns
are presented in Table 2. Bexarotene (4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-
yl)ethenyl]benzoic acid) mainly underwent an oxidative degradation process. Photoox-
idation was caused by UV irradiation in the presence of the photocatalysts TiO2/ZnO.
Under these conditions, hydroxyl radicals (HO·) were formed, which then underwent
a radical substitution reaction [36,37]. Pathways of degradation of bexarotene involve
hydroxylation of the tetrahydronaphthalene ring to 7-hydroxy-5,6,7,8-tetrahydronaphtyl
(7-hydroxy-bexarotene—BEXP-4), which could lead to 7-oxo-5,6,7,8-tetrahydronaphtyl
(7-oxo-bexarotene—BEXP-3) and ultimately could lead to the cleavage of the ring (BEXP-1).
The other possibility is oxidation of the methyl group in position 3 of tetrahydronaphtha-
lene ring to the corresponding carboxyl group (BEXP-1 and BEXP-4), or the formation of
BEXP-2 (4-(3,5,5,8,8,-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl) carbonyl) benzoic acid).
BEXP-2 is used as a substrate to synthesize bexarotene with Grignard reagent in a solvent
(e.g., diethyl ether, tetrahydrofuran, ethylene glycol, dimethyl ether) followed by dehy-
dration using p-toluene sulfonic acid. BEXP-2 was also described as one of the two major
impurities—identified as Impurity B in the patent: “Process for the preparation of highly
pure bexarotene” [38].
Table 1. Proposed structures of degradation products of bexarotene.
Compound RT[min] [M+H
+] Fragmentation Ions Structure
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9. UV Irradiation of Bexarotene in Solution in the Presence of UV Absorbers 
In Europe, Annex VI to the EU Cosmetics Regulation contains 29 substances. The list 
includes only two physical filters: zinc(II) oxide and titanium(IV) oxide. They are ac-
cepted in both Europe and the USA. The benefit of these absorbers is a wide spectrum of 
UV protection, both against UVA and UVB. Zinc oxide has been extensively applied in 
cosmetics, including personal care products and pharmaceuticals. However, the high 
photocatalytic activity of TiO2 and ZnO could promote the degradation of the parent 
drug by generation of reactive oxygen species (ROS), mainly hydroxyl radicals (OH•) and 
oxygen radicals (O•), resulting in the oxidation of the organic compound [10,39]. 
The photostability testing of bexarotene was performed in solutions with and 
without the presence of UV absorbers. Irradiation was conducted for 1 h. Bexarotene 
degradation was observed only in the sample containing the ZnO/TiO2 mixture. In con-
trol samples containing bexarotene or bexarotene in the presence of UV filters, the tested 
substance remained stable (Figure 2). MBC isomerization was only observed (the addi-
tional peak on the chromatogram m/z = 255 corresponds to MBC). In the presence of 
ZnO/TiO2, a photocatalytic degradation of bexarotene was observed; several degradation 
products were recorded on chromatograms, and the probable structures of four of them 
are presented in Table 1. 
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and the type of catalyst applied influenced the quantitative and qualitative composition of
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was observed with TiO2 and ZnO/TiO2 application than with ZnO application (p < 0.05).
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10. UV Irradiation of Bexarotene in Formulations
Stability of the active substance contained in the drug form may differ from its stability
in the powder or solution form; hence, it is valid to conduct stability testing of active
pharmaceutical ingredients and finished pharmaceutical products. For a medicinal product,
the presence of auxiliary substances may impact the kinetics of the degradation of the
active substance. Photostability testing of bexarotene in the prepared formulations was
conducted by irradiation of gel containing the investigated substance and gel containing
bexarotene in the presence of selected chemical and physical UV absorbers. For our study,
the prepar d b xarotene gel with 1 mg g−1 was us d. The prepared 50 mg samples were
irradiated on PMMA plates for 2 h. In addition, dark control samples were also developed
(the tested sample was wrapped in aluminum foil and irradiated for 2 h). The percentage
of bexarotene content in the tested samples is shown in Figure 4.
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in experimental conditions. No changes in bexarotene concentration were observed af-
ter 2 h of irrad ation wi h chemical filters: BP-1, BP-2, 4-MBC, and BP-4. Bexarotene
u derwe t degradation in the presence of avobenzone or physical UV filters. The influ-
ence of formul tion on the stability of the active substance should be emphasized here:
bexaroten in gel in the presence of avobenzone underwent almos complete photodegra-
da , whereas in the same combinati n in ethanol solution, it remained stable (Figure 4).
Moreover, it is well known that UV filters can exhibit photostabilizing effects, but may
als contribute to ccelerating degradatio of ctive pharmaceutical ingr dients under UV
irradiation [36,39]. In the case of bexarotene, its photostability was affected by AVB, BP-3,
meradimate, and homosalat .
10.1. In Vitro Antiproliferative Assays
In vitro antiproliferative assays following photocatalytic degradation in experimental
conditions were determined in vitro against cervical (HeLa), breast (MDA-MB-231), and
ovarian cancer (A2780), as well as non-cancerous murine fibroblast (NIH/3T3) cell lines,
by means of MTT assays. Cells were treated with 3, 10, and 30 µM of solution after UV
irradiation (B0—without irradiation, B1—1 h, B2—2 h, and B4—4 h). The results are shown
in Figure 5. The in vitro cytotoxicity risk evaluation based on photocatalytic degradation of
bexarotene indicated substantial antiproliferative action at concentrations of 10 or 30 µM.
HeLa cells seemed outstandingly sensitive, exhibiting significant inhibition of proliferation
at even 3 µM of B4. Treatment of A2780 cells with bexarotene without irradiation resulted
in pronounced growth inhibition at 30 µM, followed by a biphasic action in terms of the
irradiation time. This biphasic character can be detected on HeLa cells as well, indicating
that antiproliferative metabolites could be generated during the irradiation of bexarotene in
a time-dependent way, and the produced metabolites are different in terms of cell-growth-
inhibiting properties. Non-cancerous murine fibroblasts (NIH/3T3) exhibited marked
concentration-dependent inhibition by bexarotene, while the degradation products elicited
a more pronounced antiproliferative action only at the highest applied concentration.
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10.2. In Silico Toxicity Predictions
The toxicities of bexarotene and all its identified photodegradation products were
assessed with the OSIRIS Property Explorer server. None of the degradation products
turned out to be harmful in terms of the mutagenic, tumorigenic, or irritant proprieties.
Bexarotene and BEXP-4 demonstrated a positive risk assessment in terms of reproductive
effects, which was related to the 1,1-diphenylethylene moiety.
11. Conclusions
The present article provides, for the first time, an insight into the photodegradation
pathways of bexarotene, and reports the possible degradation products of this substance.
In line with the ICH guidelines, photostability testing constitutes an integral part of in-
vestigating the stability of medicinal substances and pharmaceutical products. To assess
bexarotene’s photostability, a new UPLC method was developed to determine the inves-
tigated compound in the presence of its degradation products. Due to its polyaromatic
structure, bexarotene remained stable under the experimental conditions in ethanol solu-
tion after UV irradiation, except in the presence of TiO2 and ZnO. No changes in bexarotene
concentration in the gel formulation were observed after irradiation with the chemical
filters BP-1, BP-2, 4-MBC, and BP-4, but it underwent degradation in the presence of
avobenzone or physical UV filters. This study revealed the impact of the presence of
UV absorbers on the photostability of bexarotene in formulation. Non-cancerous murine
fibroblasts showed a marked concentration-dependent inhibition by bexarotene, while the
solution after photodegradation of bexarotene elicited a more pronounced antiproliferative
effect only at the highest applied concentration.
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36. Kryczyk-Poprawa, A.; Żmudzki, P.; Koczurkiewicz, P.; Pękala, E.; Hubicka, U. Photostability of Terbinafine Under UVA
Irradiation: The Effect of UV Absorbers. Photochem. Photobiol. 2019, 95, 911–923. [CrossRef]
37. Farner Budarz, J.; Turolla, A.; Piasecki, A.F.; Bottero, J.Y.; Antonelli, M.; Wiesner, M.R. Influence of Aqueous Inorganic Anions on
the Reactivity of Nanoparticles in TiO2 Photocatalysis. Langmuir 2017, 33, 2770–2779. [CrossRef] [PubMed]
38. Bhirud, S.B.; Sarin, G.S.; Sharma, B.K.; Gera, P. Process for the Preparation of Highly Pure Bexarotene. WO2011141928A1,
9 March 2011.
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